Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,454 total articles

AMC Robotics Makes Strategic Investment in Etronium AI, an Agentic Edge AI Company Founded by Duke University Professors

AMC Robotics Makes Strategic Investment in Etronium AI, an Agentic Edge AI Company Founded by Duke University Professors

AMC Robotics announced a strategic investment in Etronium AI via two SAFEs, gaining early access to groundbreaking hardware-in-the-loop AI technology developed by Duke University professors. This platform enables AI systems to write and test code directly on hardware, significantly reducing prototype times and improving reliability for AMC Robotics…

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

RenovoRx, a Nasdaq-listed life sciences company, announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23, 2026. The presentation will cover RenovoRx's record first quarter 2026 revenue driven by increasing adoption of its FDA-cleared RenovoCath drug-delivery device, progress on the…

Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals announced that Japan’s Ministry of Health, Labour and Welfare granted Orphan Drug Designation to their drug candidate QRX003 for Netherton Syndrome, a rare genetic skin disorder with no approved treatments. This designation offers development incentives including market exclusivity, building on previous orphan and fast track d…

CPI Aero Announces New Long Term Supply Agreement to Manufacture Engine Air Inlet Assemblies for Embraer Phenom 100EX

CPI Aero Announces New Long Term Supply Agreement to Manufacture Engine Air Inlet Assemblies for Embraer Phenom 100EX

CPI Aerostructures announced a life-of-program supply agreement with Embraer to manufacture engine inlet assemblies for the Embraer Phenom 100EX business jets, expanding on their existing work with the Phenom 300E series. The agreement highlights CPI Aero's continued leadership in aerospace aerostructures and adds to their substantial backlog.

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Fate Therapeutics showcased data for its off-the-shelf CAR T-cell therapies FT819 and FT839 targeting autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis at the 2026 European Congress of Rheumatology. FT819 demonstrated rapid and sustained clinical improvements with a favorable safety profile and successful outpa…

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

Teva Pharmaceutical Industries Ltd. has begun launching AHZANTIVE®, an EMA-approved biosimilar to Eylea® (aflibercept), across multiple European countries. This launch broadens Teva's biosimilar portfolio, strengthens its presence in ophthalmology, and supports its Pivot to Growth strategy by improving patient access to biologic medicines for retin…

High Roller Technologies to Launch ROLR Brand with $25 Million Free-To-Trade Prediction Challenge Ahead of Official Prediction Markets Product Release

High Roller Technologies to Launch ROLR Brand with $25 Million Free-To-Trade Prediction Challenge Ahead of Official Prediction Markets Product Release

High Roller Technologies, Inc. announced the launch of its new prediction markets brand, ROLR, paired with a $25 million free-to-trade prediction challenge. The eight-week competition rewards traders weekly with cash prizes and culminates in a grand prize of $25 million. This initiative precedes the official launch of ROLR’s prediction markets prod…

Vivakor Secures One-Year Crude Oil Transaction Representing Approximately $108 Million Annualized Revenue

Vivakor Secures One-Year Crude Oil Transaction Representing Approximately $108 Million Annualized Revenue

Vivakor, Inc. has secured a one-year recurring crude oil transaction through its trading platform, covering approximately 100,000 barrels per month at the Cushing Terminal. This deal is estimated to generate about $108 million in annualized revenue, reinforcing the company's strategy of integrating crude oil marketing with its midstream infrastruct…

Trident Digital Launches TDTHAI Africa to Pursue AI-Powered Digital Infrastructure Opportunities Across Emerging African Markets

Trident Digital Launches TDTHAI Africa to Pursue AI-Powered Digital Infrastructure Opportunities Across Emerging African Markets

Trident Digital Tech Holdings Ltd., a Nasdaq-listed Singapore-headquartered digital infrastructure company, announced the launch of TDTHAI Africa, an AI-driven platform aiming to capitalize on digital infrastructure opportunities in Africa. Building on their Ghana deployment serving over 530,000 MSMEs with projected revenues of $800 million over fi…

Nexera Technologies Announces Receipt of Nasdaq Listing Approval for Majority-Owned Subsidiary Fort Technology

Nexera Technologies Announces Receipt of Nasdaq Listing Approval for Majority-Owned Subsidiary Fort Technology

Nexera Technologies Ltd announced that its majority-owned subsidiary, Fort Technology Inc., has received formal Nasdaq approval to list its common shares on the Nasdaq Capital Market under the ticker symbol "FRTT." Fort Technology's shares will continue trading on the TSX Venture Exchange. Nexera holds approximately 70.94% equity in Fort Technology…

MACOM IMS 2026 Product Announcements for Aerospace and Defense

MACOM IMS 2026 Product Announcements for Aerospace and Defense

MACOM Technology Solutions Inc. announced a new portfolio of high-performance RF solutions designed to meet stringent aerospace and defense requirements. These include high-power amplifiers and front-end modules across S-Band, C-Band, X-Band, and wideband frequencies, incorporating GaN and GaAs technologies to enhance radar, communications, and ele…

Xos announces $6 million common stock registered direct offering

Xos announces $6 million common stock registered direct offering

Xos, Inc., a US-based leader in electric commercial vehicles and energy storage systems, has announced a registered direct offering of approximately 1.1 million shares of common stock at $5.50 per share, intending to raise about $6 million in gross proceeds. The company plans to use the funds to expand its Power Hub and energy storage business targ…

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Emergent BioSolutions Inc. supports National Naloxone Awareness Day through partnership with Victoria's Voice Foundation to promote opioid overdose education and expand access to NARCAN® Nasal Spray and KLOXXADO® Nasal Spray. The company highlights new initiatives including the NARCAN® Nasal Spray Carrying Case and upcoming outreach in colleges to …

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Immutep Limited announced positive interim Phase I clinical trial results for IMP761, a first-in-class LAG-3 agonist antibody targeting autoimmune diseases. The single ascending dose study demonstrated favorable safety, tolerability, and significant pharmacodynamic activity at 7 mg/kg in healthy volunteers. These findings support further clinical d…

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Arvinas, Inc. announced its participation in the Michael J. Fox Foundation-supported LRRK2 Investigative Therapeutics Exchange (LITE) and Parkinson’s Precision Medicine Initiative (PPMI) programs. This collaboration aims to advance ARV-102, an investigational PROTAC drug targeting LRRK2 for treating Parkinson’s disease and related neurodegenerative…

IMUNON Announces Up to $10 Million Cash Financing

IMUNON Announces Up to $10 Million Cash Financing

IMUNON, Inc. announced a structured financing deal raising up to $10 million to fund enrollment in its pivotal Phase 3 OVATION 3 trial of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The financing combines preferred stock issuance and secured promissory notes with favorable terms intended to minimize dilution. Recent Phase 2 …